HSSP INTL (03626) has been renamed to "Qiming Eastern Holdings Limited"
HSSP
INTL (03626) has announced that the special resolution to change the company name was approved by shareholders at the annual general meeting held on December 5, 2025. The Registrar of Companies in the Cayman Islands has issued a certificate of name change, confirming that the company's English name has been changed from "Hang Sang (Siu Po) International Holding Company Limited" to "East Nova Holdings Limited". The Chinese dual foreign name "" was also adopted on December 8, 2025.
HSSP
INTL(03626) announced that after the special resolution to change the company name was passed by the shareholders at the annual general meeting held on December 5, 2025, the Registrar of Companies in the Cayman Islands has issued a certificate of change of name, indicating that the English name of the company has been changed from "Hang Sang (Siu Po) International Holding Company Limited" to "East Nova Holdings Limited", and the Chinese dual foreign name "" was adopted on December 8, 2025. The Registrar of Companies in Hong Kong issued a certificate of registration of change of name on December 22, 2025, confirming that the company has changed its name to "East Nova Holdings Limited" in English and "" in Chinese, as registered in Hong Kong under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong).
The English trading symbol of the company's shares on the Stock Exchange will be changed from "HSSP INTL" to "EAST NOVA HLDGS", and the Chinese trading symbol will be "", effective from 9:00 am on January 7, 2026.
Related Articles

BEISEN HOLDING (09669) spent 583,200 Hong Kong dollars on January 2 to repurchase 80,000 shares.

IMPERIUM FIN GP (08029): Lin Junwei appointed as executive director

CSPC PHARMA (01093): Nintedanib Ethanesulfonate Inhalation Powder Aerosol Approved for Clinical Trials in China.
BEISEN HOLDING (09669) spent 583,200 Hong Kong dollars on January 2 to repurchase 80,000 shares.

IMPERIUM FIN GP (08029): Lin Junwei appointed as executive director

CSPC PHARMA (01093): Nintedanib Ethanesulfonate Inhalation Powder Aerosol Approved for Clinical Trials in China.






